Inhibitors of microbial beta-glucuronidase enzymes and uses thereof

Patent metadata

Field	Value
Publication number	US-11339178-B2
Application number	US-201716318991-A
Country	US
Kind code	B2
Filing date	Jul 20, 2017
Priority date	Jul 21, 2016
Publication date	May 24, 2022
Grant date	May 24, 2022

Abstract

Compounds and compositions are provided that comprise selective b-glucuronidase inhibitors. The compounds and compositions can ameliorate the side effects of chemotherapeutic agents and can improve the efficacy of such agents, including irinotecan and non-steroidal anti-inflammatory drugs.

First claim

That which is claimed:

1. A compound of Formula I:

or a pharmaceutically acceptable salt thereof,
wherein,
R 1 is

wherein t and q are each 1, R 7 is H, and R 8 is H;

R 2 is —NR F R G , wherein;
R F and R G are independently selected from the group consisting of H, linear or branched C 1-6 alkyl optionally substituted with halo, amino or hydroxyl, optionally substituted benzyl, and C 3-8 cycloalkyl;
and

R 4 and R 5 are taken together with the carbon to which each is attached to form an optionally substituted cyclohexyl ring.

2. A compound having the structure

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , which is selected from

Assignees

• Univ North Carolina Chapel Hill

Inventors

• Redinbo Matthew R
• Jin Jian
• James Lindsey
• Pellock Sam
• Ariyarathna Ranathunga Arachchillage Yamuna
• Frye Stephen

Classifications

• C07D513/14 Primary

  Ortho-condensed systems · CPC title

• C07D495/14 Primary

  Ortho-condensed systems · CPC title

• C07D519/00

  Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 · CPC title

• A61P1/12

  Antidiarrhoeals · CPC title